Reducing Amidated Amino Acids in Cell Lines for Protein Expression
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The production of proteins, particularly biopharmaceuticals, is challenging due to the complexity of controlling post-translational modifications in living cell cultures, leading to undesired heterogeneity and potential immunogenicity issues caused by amidated amino acids, which can affect protein activity and consistency.
Innovation Solution
The development of cell lines with reduced peptide amidation activity through methods such as gene silencing, gene knock-down, or expression of dysfunctional enzymes to inhibit peptide amidation, allowing for controlled post-translational modifications and improved protein production processes.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If peptide amidation activity is high in cell lines, then protein production yield is improved, but protein heterogeneity and immunogenicity increase
Solution Approach 1:
The patent applies local quality by specifically targeting and modifying the peptide amidation function in cell lines through genetic engineering. By introducing mutated versions of peptidylglycine alpha-amidating monooxygenase with altered catalytic activity, the invention creates a localized functional change in the cell's post-translational modification capability, allowing high protein yield while controlling amidation-related heterogeneity
Solution Approach 2:
The patent changes the catalytic parameters of the peptide amidation enzyme by using mutated forms of PAM with different activity levels. By adjusting the enzymatic activity parameter through genetic modification, the invention achieves optimal balance between protein production efficiency and product homogeneity, reducing unwanted amidated variants while maintaining yield
2Productivity
If peptide amidation activity is high in cell lines, then protein production yield is improved, but immunogenicity and safety risks increase
Solution Approach 1:
The patent applies local quality by specifically targeting and modifying the peptide amidation function in cell lines through genetic engineering. By introducing mutated versions of peptidylglycine alpha-amidating monooxygenase with altered catalytic activity, the invention creates a localized functional change in the cell's post-translational modification capability, allowing high protein yield while controlling amidation-related heterogeneity
Solution Approach 2:
The patent changes the catalytic parameters of the peptide amidation enzyme by using mutated forms of PAM with different activity levels. By adjusting the enzymatic activity parameter through genetic modification, the invention achieves optimal balance between protein production efficiency and product homogeneity, reducing unwanted amidated variants while maintaining yield
3Manufacturing precision
If peptide amidation activity is reduced in cell lines, then protein homogeneity is improved, but production yield may decrease
Solution Approach 1:
The patent applies partial action by using mutated PAM enzymes with reduced but not completely eliminated amidation activity. This partial inhibition strategy allows sufficient protein production while adequately controlling heterogeneity, avoiding the complete loss of yield that would result from total enzyme inactivation
Solution Approach 2:
The patent changes the catalytic parameters of the peptide amidation enzyme by using mutated forms of PAM with different activity levels. By adjusting the enzymatic activity parameter through genetic modification, the invention achieves optimal balance between protein production efficiency and product homogeneity, reducing unwanted amidated variants while maintaining yield
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach enables the reduction of amidated amino acids, enhancing protein production consistency, safety, and efficacy by minimizing heterogeneity and immunogenicity, thereby improving the quality and yield of biopharmaceuticals.
Implementation Method 1
The peptide amidation is catalysed by the enzyme peptidylglycine alpha-amidating monooxygenase (PAM)
Data Source
Figure 1~2
Figure 3~4
Figure 5~6
AI summary
The present invention is related to a method to reduce peptide amidation activity in a given cell line, cell lines with reduced peptide amidation activity, and uses thereof.